Fig. 1From: Axicabtagene ciloleucel CD19 CAR-T cell therapy results in high rates of systemic and neurologic remissions in ten patients with refractory large B cell lymphoma including two with HIV and viral hepatitisResponse to treatment after axicabtagene ciloleucel. Swimmer’s plot showing response to treatment after Axi-cel infusion in patients with DLBCL receiving CD19-directed CAR-TBack to article page